Clinical Trial Update: Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm [Phase 2]

View source ↗

Summary

This Phase 2 trial update reports completion of a study evaluating the combination of ruxolitinib phosphate and azacitidine in patients with myelofibrosis or my…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Thrombocythemia
• Myelodysplastic Myeloproliferative Neoplasm Unclassifiable
• Myelofibrosis
• Polycythemia Vera

Drugs mentioned

• Jakafi (ruxolitinib)
• VIDAZA (AZACITIDINE)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Myelofibrosis Transformation in Essential Thrombocythemia | Phase 2 | Status: COMPLETED